STOCK TITAN

Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, will release its Q3 2020 financial results on November 5, 2020, post-market. A conference call and webcast will be held at 2:00 PM PT / 5:00 PM ET to discuss these results and recent developments. The company specializes in advanced genomic solutions for cancer, utilizing its ImmunoID NeXT Platform to analyze 20,000 human genes and immune responses from patient samples. Personalis is also partnering with the VA Million Veterans Program to sequence over two million veteran genomes.

Positive
  • Upcoming Q3 2020 financial results announcement could indicate growth.
  • Partnership with VA Million Veterans Program to sequence veteran genomes enhances credibility.
Negative
  • None.

MENLO PARK, Calif.--()--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (866) 220-8061 for domestic callers or (470) 495-9168 for international callers, using conference ID: 9697771. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue or blood sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over two million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Contacts

Investor Relations Contact:
Caroline Corner
investors@personalis.com
415-202-5678

Media Contact:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300

FAQ

When will Personalis release its Q3 2020 financial results?

Personalis will release its Q3 2020 financial results on November 5, 2020.

What is the conference call ID for Personalis' Q3 2020 financial results?

The conference call ID for the Q3 2020 financial results is 9697771.

How can I access the live webinar for Personalis' financial results?

The live webinar can be accessed via the Events section on Personalis' website.

What is the main focus of Personalis, Inc.?

Personalis focuses on advanced genomics for cancer, providing detailed molecular data on patient cancers.

Personalis, Inc.

NASDAQ:PSNL

PSNL Rankings

PSNL Latest News

PSNL Stock Data

241.62M
54.05M
19.3%
53.15%
4.58%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FREMONT